Clinical Characteristics and Survival Analysis of Single Center Adult Chronic Myeloid Leukemia in Chronic Phase
10.19746/j.cnki.issn1009-2137.2024.05.012
- VernacularTitle:单中心成人慢性髓系白血病慢性期临床特点和生存分析
- Author:
Xia-Xia JIAO
1
;
Yuan-Yuan ZHANG
;
Jing PAN
;
Lei-Na SONG
;
Cai-Qin LIN
;
Hui-Zhen SHI
;
Bin ZHU
;
Su-Li WANG
;
Shao-Ying PAN
;
Zhi-Yong DING
;
Wen-Li ZHAO
Author Information
1. 上海交通大学附属第六人民医院南院,上海 201400
- Keywords:
chronic myeloid leukemia;
tyrosine kinase inhibitor;
clinical characteristics;
efficacy;
adverse reactions
- From:
Journal of Experimental Hematology
2024;32(5):1381-1387
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics and prognosis of single center adult chronic myeloid leukemia in chronic phase(CML-CP).Methods:Clinical data of 41 adult CML-CP patients in Department of Hematology,Shanghai Fengxian District Central Hospital from January 2015 to May 2021 were retrospectively analyzed.The clinical characteristics and prognosis of patients between＜60 years group and ≥ 60 years group were compared.Results:The 41 patients included 27(65.9％)males and 14(34.1％)females.The median age of the patients was 56(19-84)years,with 22 cases(53.7％)＜60 years and 19 cases(46.3％)≥60 years.Univariate analysis indicated that the proportions of patients with comorbidities,intermediate/high-risk Sokal score,myelofibrosis,and lactate dehydrogenase ≥1 000 U/L were significantly increased in ≥60 years group compared with＜60 years group at initial diagnosis(all P＜0.05).There were no statistical differences in the distribution of sex,ELST score,white blood cell count,platelet count,peripheral blood basophil percentage,peripheral blood eosinophil percentage and bone marrow primitive cell percentage between the two groups(P＞0.05).The proportion of patients taking reduced-dose imatinib in≥60 years group significantly increased(P＜0.001).Patients＜60 years had a higher proportion of molecular biological remission after treatment of tyrosine kinase inhibitors(TKIs)than patients ≥ 60 years(P＜0.001).The incidence of non-hematologic adverse reactions to TKI therapy significantly increased in patients ≥ 60 years(P＜0.001).Multivariate analysis showed that no adverse factors affecting the efficacy and prognosis of TKI.Conclusion:Compared with adult CML-CP patients＜60 years,patients ≥ 60 years gain fewer benefits from TKI treatment and increased adverse reactions.
